2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 501

Change in RF Titers Reflects RA Disease Activity and Predicts Therapeutic Response during TNF Inhibitor Therapy; Patients with a Continuous Reduction of Serum RF Levels Show Good Response
Abstract Number: 502

Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Abstract Number: 503

Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients
Abstract Number: 504

Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Abstract Number: 505

Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Abstract Number: 506

Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Abstract Number: 507

Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Abstract Number: 508

Impact of Race on Patient Global Scores and the Misclassification of Disease Activity
Abstract Number: 509

In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters
Abstract Number: 510

Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare
Abstract Number: 511

Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
Abstract Number: 512

Physical Function and Inflammatory Activity in Rheumatoid Arthritis Patients. Is Disease Duration Important?
Abstract Number: 513

Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
Abstract Number: 514

MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort
Abstract Number: 515

Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].